NYSE: STVN

Stevanato (STVN) Stock Analysis & Forecast

Nov 13 close

$15.80+1.44 (+10.0%)

Gekko Brief

AI summaryNov 9 close

Stevanato's week centers on the fallout from its Q3 2026 results, reported 3 November, where revenue grew 8% and adjusted EBITDA margin expanded 150 bps to 27.2%, but GLP-1 revenue fell to 17-18% of total revenue and shares dropped roughly 28%. William Blair downgraded the stock to Market Perform from Outperform, citing concerns over the 2027 outlook, persistent Engineering segment issues (down 12% organically), and lower GLP volume growth from a major customer. The sharp decline has also drawn multiple securities fraud investigation announcements from law firms examining whether the company complied with federal securities laws.

Shares closed at $13.73, up 1.2% on the day, but remain well below both the 50-day ($19.67) and 200-day ($17.96) moving averages, with one-month returns at -29.2% and one-year returns at -43.8%. The GekkoIndex reads 79.5, placing the stock in the Buying zone, and the gap to Gekko Fair Value of $20.87 stands at -34.2%.

The next earnings date falls on 3 March 2027, 113 days out and beyond a typical 20-day holding window. No insider, Congress, or unusual options activity appears in the current windows. Seasonality for this point in the calendar shows a -3.7% average move over the next 20 trading days across 5 years, with gains in 2 of those years, a factor worth noting given the stock's typical 20-day move of 7.8%.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Stevanato price vs fair value

$19.27$15.80Nov ’25May ’26Nov ’26
Close $15.80200-day averageGekko Fair Value $19.27

Stevanato quick facts

Market cap
$4.32B
P/E ratio
24.3
Forward P/E
21.7
EPS, TTM
$0.59
Revenue, TTM
$1.25B
Profit margin
11.3%
Dividend yield
0.00%
Beta
0.80
Volume
1.46M avg 1.25M
1-year return
−33.3%
Typical daily move
±9%
Typical 20-day move
±7.9%
50-day average
$19.15
200-day average
$17.92
Next earnings
Mar 3 before open
Shares outstanding
49.83M
52-week range
$12.05$24.01

Stevanato swing-trade checklist

Stevanato scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive1 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $15.80 sits between the 50-day ($19.15) and 200-day ($17.92) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    63.8, Accumulation

    Reading 63.8 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    18.0% below

    Price is 18% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 2 open-market insider purchases.

    See smart money
  • Earnings risksupportive

    Reports in 108 days

    Next report Mar 3, 2027, 108 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +4.6% on average

    From this point in the calendar, the next 20 trading days averaged +4.6% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Stevanato stock chart and price history

Stevanato closed at $15.80 on Nov 13, 2026, −33.3% over the past year, inside a 52-week range of $12.05 to $24.01.

Close50-day average200-day averageVolume
Stevanato share price, past year, with 50-day and 200-day moving averages and volume$20$25DecJan 2026FebMarAprMayJunJulAugSepOctNov15.80

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−17.9%
3 months
−25.7%
6 months
−12.2%
1 year
−33.3%
The full STVN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open STVN in Gekko

Follow Stevanato through every session

Put STVN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track STVN in GekkoFree for 7 days. No credit card required.

About Stevanato

Stevanato develops and produces packaging and delivery equipment used across the pharmaceutical and healthcare fields. Customers rely on it for containment products, drug delivery systems, and medical devices, as well as diagnostic and analytical support, and it has built recognition around this mix of components serving drugmakers and health providers.

Beyond these products, the company builds machinery for jobs like inspecting finished goods visually, assembling parts, packaging output, and shaping glass. It sits within a larger corporate group, operating as a subsidiary of Stevanato Holding S.R.L., while carrying out its manufacturing and engineering work under its own brand.

The company dates back to 1949 and keeps its principal base in Piombino Dese, Italy. Its stock trades on the NYSE under the ticker STVN.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
stevanatogroup.com

Stevanato GekkoIndex: the smart money zone

Stevanato’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.8, in the Accumulation zone, down 18.5 points over five sessions.

010063.8Accumulation

Down 18.5 points over five sessions, from the Buying zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying45+1.0%+0.2%+0.7%−1.6%
Accumulation (current zone)267+0.5%+0.9%−0.2%−1.1%
Neutral363−0.8%−1.1%−1.4%−1.6%
Distribution19−4.0%−5.7%−3.7%−7.2%
Selling8Too few readings yet

Average STVN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the STVN price, zone by zone.Track STVN in Gekko

Is Stevanato stock overvalued? Gekko Fair Value

Stevanato trades 18.0% below Gekko Fair Value of $19.27, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Stevanato shares are worth, recalculated every trading day.

$19.27

Gekko Fair Value, Nov 14, 2026

18.0% Undervalued

At the end of Aug 2026 the price was 7.4% below the estimate.

Gekko Fair ValueShare price, month end
$19$16Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open STVN in Gekko

Stevanato insider and Congress trading

Insiders filed 2 open-market purchases in Stevanato worth $601K, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$601Kin 2 open-market purchases

FiledInsiderTypeSharesValue
Nov 12FEDERICI WILLIAM J
director
Purchase20,000$274K
Nov 10MOREL DONALD E JR
director
Purchase25,000$327K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in STVN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for STVN, plotted on the chart in Gekko.Open STVN in Gekko

Stevanato earnings: next date and track record

Stevanato reports on Mar 3, 2027, before the open (108 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±9.9%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

+13.1%Mar ’25+10.1%May ’25−6.0%Aug ’25−3.6%Nov ’25+8.0%Mar ’26−4.1%May ’26−2.4%Aug ’26−31.9%Nov ’26

Last earnings call, Nov 3, 2026 AI summary

What they said
Stevanato Group reported Q3 results in line with expectations, with reported and organic revenue growing 8%. High-value solutions represented 46% of total revenue, and adjusted EBITDA margin expanded 150 bps to 27.2% YoY. BDS segment grew 11% organically, offsetting a 12% engineering decline. GLP-1 revenue fell to 17-18% of total revenue, while non-GLP biologics surged 30% in the quarter.
Guidance
Management expects a temporary growth moderation in fiscal 2027 due to lower GLP-1 volumes, though majority of lost revenue has been backfilled. Non-GLP biologics demand expected to remain strong in 2027. Customer forecast process ongoing, with trends consistent with 2026 performance.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 3, 2026$0.18
est $0.18
+1.4%$369.4M
est $363.3M
+1.7%−31.9%
Aug 4, 2026$0.16
est $0.14
+10.5%$344.9M
est $340.6M
+1.3%−2.4%
May 7, 2026$0.13
est $0.12
+8.3%$316.1M
est $310.5M
+1.8%−4.1%
Mar 4, 2026$0.21
est $0.20
+5.0%$407.0M
est $391.3M
+4.0%+8.0%
Nov 6, 2025$0.14
est $0.13
+7.7%$355.1M
est $385.5M
−7.9%−3.6%
Aug 5, 2025$0.11
est $0.10
+10.0%$329.7M
est $343.2M
−3.9%−6.0%
May 8, 2025$0.10
est $0.09
+11.1%$281.3M
est $301.6M
−6.7%+10.1%
Mar 6, 2025$0.19
est $0.18
+5.6%$342.3M
est $268.2M
+27.7%+13.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Stevanato stock forecast and analyst price targets

Analysts’ average 12-month price target for Stevanato is $19.46, +23.2% from the last close, from 8 firms rating the stock in the last 90 days.

$19.46consensus 12-month target, +23.2% from the last close
Low $16High $25
Buy4
Hold4
Sell0

Each firm’s latest rating in the last 90 days: 8 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 4CitiBuy, maintained$20+26.6%
Nov 4UBSHold, maintained$16+1.3%
Nov 4William BlairHold, downgraded——
Nov 4Bank of America SecuritiesBuy, maintained——
Nov 3KeyBancBuy, maintained$25+58.2%
−0.2%average 20-day move after past Accumulation readings
+4.6%average move over the next 20 trading days in the last 5 years
±9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Stevanato seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Stevanato averaged +4.6% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+3.4%2021+17.4%2022−3.8%2023+13.7%2024−3.5%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.4%2 of 5
Next 10 trading days−0.4%3 of 5
Next 15 trading days−1.1%2 of 5
Next 20 trading days+4.6%3 of 5
Next 30 trading days+1.6%2 of 5

For scale, STVN’s typical 20-trading-day move in either direction is about 7.9%.

Stevanato market cap and key statistics

Stevanato’s market cap is $4.32B, with a P/E ratio of 24.3 and revenue of $1.25B over the last twelve months.

Valuation

Market cap
$4.32B
P/E ratio
24.3
Forward P/E
21.7
EPS, TTM
$0.59
Gekko Fair Value
$19.27

Trading

Volume
1.46M
Avg volume, 20 days
1.25M
52-week high
$24.01
52-week low
$12.05
Shares outstanding
49.83M

Financials

Revenue, TTM
$1.25B
Profit margin
11.3%
Return on equity
9.3%
Quarterly earnings growth, YoY
+15.4%

Risk and income

Beta
0.80
Typical daily move
±9%
Typical 20-day move
±7.9%
Dividend yield
0.00%

Stevanato stock news this week

2 headlines about Stevanato from the past week, newest first, each linking to the publisher.

Stevanato peers

Stevanato’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Stevanato stock FAQ

What is Stevanato’s market cap?

Stevanato’s market cap is $4.32B at the Nov 13, 2026 close of $15.80, with 49.83M shares outstanding. The shares trade on a P/E ratio of 24.3.

What is the Stevanato stock forecast?

The consensus analyst 12-month price target for Stevanato is $19.46, +23.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 4 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Stevanato stock overvalued or undervalued?

On Gekko’s estimate Stevanato is undervalued: the Nov 13, 2026 close of $15.80 is 18.0% below Gekko Fair Value of $19.27. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Stevanato report earnings next?

Stevanato is expected to report on Mar 3, 2027, before the market opens (108 days away). Analysts expect earnings of $0.22 per share on revenue of $402.1M. Stevanato beat the earnings estimate in 8 of its last 8 reports, moving 9.9% on average across the report.

What is Stevanato’s 52-week high and low?

Stevanato’s 52-week high is $24.01 and its 52-week low is $12.05; it closed at $15.80 on Nov 13, 2026, −33.3% over the past year. Over the last five years the shares peaked at $36.30 on Aug 9, 2023.

Is Stevanato stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Stevanato the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.